Time to abandon placebo control in pivotal phase III trials?

World Psychiatry

Volumn 14, Issue 3, 2015, Pages 306-307

  Geddes, John R ^a   Cipriani, Andrea ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

COMPARATIVE STUDY; DEPRESSION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; HUMAN; MAJOR DEPRESSION; MEDICAL RESEARCH; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

EID: 84942523890     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20246     Document Type: Note

References (11)

1. Institute of Medicine. Transforming clinical research in the United States: challenges and opportunities: Workshop summary. Washington: National Academies Press, 2010.
2. Khan A, Brown WA., Antidepressants versus placebo in major depression: an overview. World Psychiatry 2015; 14: 294-300.
3. Papakostas GI, Østergaard SD, Iovieno N., The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015; 76: 456-66.
4. Laughren TP., The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001; 16: 418-23.
5. Walsh BT, Seidman SN, Sysko R, et al., Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
6. Landin R, DeBrota DJ, DeVries TA, et al., The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 2000; 56: 271-8.
7. Li T, Vedula SS, Scherer R, et al., What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities. Ann Intern Med 2012; 156: 367-77.
8. Kupfer DJ, Frank E., Placebo in clinical trials for depression: complexity and necessity. JAMA 2002; 287: 1853-4.
9. Cipriani A, Furukawa TA, Salanti G, et al., Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
10. American Recovery and Reinvestment Act. Public Law 111-5, 111th Congress, 2009.
11. Norman TC, Bountra C, Edwards AM, et al., Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci Transl Med 2011; 3: 88mr1.